Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

President Donald Trump signed an executive order May 12 directing drugmakers to sell medicines in the U.S. at prices similar to those offered in other wealthy countries, or face penalties and ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's ... a strong Q1 earnings report from Lilly and immediately raised concerns from ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...

Zepbound's prescription ... struggles with supply issues in 2024. CVS's pharmacy benefit management unit, the largest in the U.S., said it would drop Zepbound coverage from July 1, but keep ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ... detention center Transgender issues are a strength for Trump ...